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service transformation. CONCLUSIONS: Currently financial incentives do not 
always encourage providers to transform services or to work collaboratively with 
each other or with commissioners of care.  
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Kim JA, Karaca-Mandic P, Blewett L 
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OBJECTIVES: To examine whether utilization of antidepressants by dual eligibles 
were different under Part D compared to Medicaid period by focusing on states 
which vary baseline state Medicaid policies and wrap-around programs for  
dual eligibles to access drugs under Part D. METHODS: A pre-post study design 
with a longitudinal dataset by linking Medicaid data for 2004-2005 and 5% 
random sample of Medicare data for 2006-2007. The study population is dual 
eligibles, existing users of antidepressants in 2004 and with enrollment from 
2004-2007 in eight states. We employ a state-fixed effect model to estimate 
medication utilization using proportion of days covered (PDC), adjusting for 
beneficiaries characteristics and health status. We adopt generalized estimation 
equation (GEE) model for estimation and spline regression for investigating 
whether changes in PDCs is related to Part D. A stratified analysis is conducted 
for community based dual eligibles (n=4,703) and nursing home dual eligibles 
(n=1,504) separately. RESULTS: Adjusted PDCs increased to 4.25 percentage  
point among community dual eligibles (p=0.00) but did not change among 
nursing home dual eligibles (p=.74) under Part D. Adjusted changes in PDCs  
were not significant for most states, except Arkansas community based dual 
eligibles (p=0.00), Florida nursing home dual eligibles (p=0.03) and New Mexico 
nursing home dual eligibles (p=0.01), which had significant increases under  
Part D. Separate spline regression for these states indicated that trends in  
PDC before and after Part D were not significantly different, suggesting  
that changes were not related to transition to Part D. CONCLUSIONS: We did not 
find empirical support for concerns regarding disruption of medication 
utilization of the dual eligible under Part D. Although states had different 
baseline Medicaid polices and wrap-around programs under Part D, lack of 
significant changes in utilization suggest that minor changes in copayments and 
refill/prescription limits etc. do not have large effect on medication utilization to 
antidepressants.  
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OBJECTIVES: Heart failure (HF) is the most frequent cause of hospitalization 
among US elderly. Despite limited evidence, current guidelines recommend the 
use of IV vasodilators in addition to IV loop diuretics (LD) for the treatment of 
acute HF (AHF) patients without hypotension. We investigated whether elderly 
patients hospitalized for AHF treated with IV LD combined with IV nitrates (NT) 
or IV nesiritide (NES) achieved better outcomes compared to those receiving IV-
LD alone. METHODS: US hospital billing records (2007-2009) from the MarketScan 
Hospital Drug Database were analyzed. Patients ≥65 years old, with an AHF 
diagnosis and no evidence of hypotension and/or cardiogenic shock were 
included. Patients receiving IV-LD alone were paired with patients receiving IV-
LD+NT and with patients receiving IV-LD+NES using propensity score matching. 
Outcomes included in-hospital mortality, length of stay (LOS), cost, and HF re-
hospitalization rate. RESULTS: Compared to IV-LD alone (N=2,918), patients 
receiving IV-LD+NT (N=2,918; mean age 78.5 years, 44.7% male) had longer LOS 
(days, ICU: 1.5 vs. 2.2; total: 5.8 vs. 7.1, p<0.01 for both), higher costs ($8,810 vs. 
$13,387, p<0.01), but similar rates of mortality (2.2% vs. 2.5%, p>0.05) and one 
year HF re-hospitalization (37.2% vs. 37.4%, p>0.05). Compared to IV-LD alone 
(N=1,561), patients receiving IV-LD+NES (N=1,561; mean age 77.8 years, 56.7% 
male) had longer LOS (days, ICU: 1.9 vs. 2.4; total: 5.9 vs. 7.8, p<0.01 for both), 
higher costs ($8,775 vs. $13,040, p<0.01), higher one year HF re-hospitalization 
rates (38.2% vs. 41.8%, p<0.05), but similar mortality rates (2.8% vs. 3.5%, p>0.05). 
CONCLUSIONS: This study amongst elderly AHF patients indicates that neither 
NT nor NES in addition to diuretics improve survival compared to diuretics 
alone, and are associated with longer LOS and higher hospitalization costs. 
These results raise the question as to whether currently utilized IV vasodilators 
are of value in the treatment of elderly AHF patients.  
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OBJECTIVES: Consumer-Driven and High Deductible Health Plans (CDHP/HDHP) 
are becoming more common in employer-sponsored plans. Approximately 60% 
of large firms offered a CDHP/HDHP in 2011. In this study we estimate the short- 
and long-term impact of enrollment in a CDHP/HDHP on use of chronic 
medications for diabetes and cardiovascular disorders. METHODS: A total of 
524,043 CDHP/HDHP enrollees age 18-64 were propensity score matched to a 
comparison group within similar firms not offering CDHP/HDHP (total 
n=1,048,086). A quarterly cross-section time series dataset was created for 
enrollees one year before and up to four years after enrollment in a CDHP/HDHP. 
The impact of CDHP/HDHP was evaluated using difference-in-differences, 
reported as a percent change in trend relative to the comparison group. 
Medication use outcomes included percent of days covered (PDC) and percent 
adherent (PDC>80%) for the following drug classes: diabetes, hypertension, 
dyslipidemia, and other cardiovascular medications, overall and for brand and 
generic drugs. Administrative claims data was obtained from the MarketScan 
Commercial Claims and Encounters Database, 2006-2010. RESULTS: One year 
after enrollment, the trend in PDC for oral diabetes medications in the 
CDHP/HDHP was 4.1% lower than the trend in the comparison group (p<0.001). In 
addition, the one-year trend in PDC for brand name oral diabetes medications 
was 10.8% lower than the comparison group (p<0.001). CDHP/HDHP enrollees 
experienced lower levels of adherence to all other drug classes within 1 year of 
enrollment. The negative impact of CDHP/HDHP on PDC grew over time. For 
example, the trend in PDC for oral diabetes medications was 34.2% lower for 
CDHP/HDHP enrollees than the comparison group (p<0.01) after four years of 
enrollment in a CDHP/HDHP. CONCLUSIONS: Enrollment in a CDHP/HDHP is 
associated with lower use of and adherence to medications for chronic 
conditions, potentially exacerbating these chronic conditions.  
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OBJECTIVES: Overweight and obesity are a growing epidemic in the US, affecting 
more than two-thirds of working-age adults. This study quantifies the economic 
burden associated with obesity from the employer’s perspective, including 
employee medical, drug, sick leave (SL), short- and long-term disability (STD; 
LTD), and workers’ compensation (WC) costs, work absence days, and self-
reported productivity. METHODS: Using a retrospective database from large 
employers throughout the US, employees’ body mass index (BMI) values (widely 
used for categorizing obesity) from 2003-2011 health risk appraisal data were 
used to create 3 cohorts: BMI<27, 27<=BMI<30, and BMI>=30. All employees were 
required to have at least 12 months of health coverage post-index (first BMI 
measurement). Medical and drug costs, SL, STD, LTD, and WC costs and absence 
days, and Health Productivity Questionnaire responses were measured 12 
months post-index and compared between cohorts using regression modeling. 
Models controlled for differences between cohorts in age, gender, marital status, 
race, salary, zip-code region, and index year. Employees with pregnancy medical 
claims were excluded. RESULTS: The study included 39,696 (BMI<27), 14,281 
(27<=BMI<30), and 18,801 (BMI>=30) eligible employees. Average age and annual 
salary were 38.8 years and $87,604 (BMI<27), 40.9 and $83,178 (27<=BMI<30), and 
40.9 and $65,843 (BMI>=30), respectively. Females represented 32.8% (BMI<27), 
22.9% (27<=BMI<30), and 38.9% (BMI>=30) of employees. Per-employee adjusted 
total annual costs (medical, drug, SL, STD, LTD, and WC combined) were $4,258 
(BMI<27), $4,873 (27<=BMI<30), and $6,313 (BMI>=30). Medical and drug costs and 
SL and WC costs and days were significantly higher for higher BMI cohorts 
(P<0.01). The BMI>=30 cohort had significantly more STD costs and days and 
lower productivity than other cohorts (P<0.001). CONCLUSIONS: Employees with 
higher BMI levels are associated with significantly more costs, more absence 
from work, and lower self-reported productivity, representing a significant 
economic burden for US employers considering the high prevalence of 
overweight and obesity.  
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OBJECTIVES: Pseudoephedrine (PSE) is used as a precursor in the illicit 
production of methamphetamine. Policies that restrict the sales of PSE have 
been adopted to curb production, which causes chemical and thermal burn 
injuries that create cost and treatment burdens on the health care system. The 
purpose of this project is to estimate the relationship between burn injuries and 
PSE sales. METHODS: PSE sales data from the National Precursor Log Exchange 
were merged with hospital discharge data from the Kentucky Cabinet for Health 
and Family Services Office of Health Policy Public Use Data Set. Kentucky 
residents with a primary diagnosis of burn (ICD-9 940.0-949.5) in 2010 were 
included. A negative binomial regression was performed with number of burns 
per county as the dependent variable. The primary explanatory variable was PSE 
sales per county (in grams/100 residents). Control variables included: % high 
school graduates over 25, urbanicity, and unemployment, all adjusted by county 
population. RESULTS: In 2010, 340 burns were treated in Kentucky facilities with 
33 counties having no burns and 94% of counties having 6 or fewer burns. Mean 
PSE sales were 49 g/100 county residents (SD=39), with a range of 0.3 g to 147 g 
per 100 county residents. A 1 gram increase in PSE sales per 100 residents was 
associated with an increase of approximately 1.1 burns per county (p<0.001). 
Controlling for population, urban counties had more burns than rural counties 
(p=0.004) and counties with higher percentages of high school graduates had 
fewer burns (p<0.001). Results were robust to various dispersion settings. 
CONCLUSIONS: These results suggest that PSE sales are associated with burn 
injuries. Limitations include missing data on cross-border PSE sales and the 
inability to distinguish methamphetamine-related burn injuries from other 
burns. These findings suggest that additional PSE sales restrictions may reduce 
the number of burn-related discharges.  
